<!DOCTYPE html>
<html>
<head>
<title>Enbrel, INN-etanercept</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ANNEX I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg powder for solution for injection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each vial contains 25 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder for solution for injection (powder for injection).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The powder is white. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate (unless contraindicated), has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not previously treated with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage as measured by X-ray and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoralen and ultraviolet-A light (PUVA) (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis. Patients treated with Enbrel should be given the Patient Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is available in strengths of 10, 25 and 50 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly has been shown to be safe and effective (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For all of the above indications, available data suggest that a clinical response is usually achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responding within this time period.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No data are available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg vial strength may be more appropriate for administration to children with JIA below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight of 25 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is administered by subcutaneous injection. Enbrel powder for solution must be reconstituted in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 ml of solvent before use (see section 6.6).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &quot;Instructions for preparation and giving an injection of Enbrel.&quot;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">provided in section 3 of the package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections, including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location, have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving Enbrel were able to mount effective B-cell immune response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(DMARD) has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">11</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and parasitic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including cysts </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin cancers* (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">melanoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">antibody positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">optic neuritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">transverse myelitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">failure congestive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bowel disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, primarily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">palms and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeletal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including 231 patients treated with Enbrel in combination with methotrexate in the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study. The observed rates and incidences in these clinical trials were similar to those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">expected for the population studied. A total of 2 malignancies were reported in clinical studies of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection, along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Streptococcal</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients. Differences from adults and other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considerations are discussed in the following paragraphs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:770pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd"> Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biological activity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses were escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial and continued for up to 24 months. Clinical improvement, including onset of action within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and was maintained for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.5. Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this study.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">18</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt;3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:78pt"><span style="font-family:Arial,sans-serif;font-size:9.9pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.93pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:398pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:233pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:404pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:458pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.9pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:138pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:154pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:183pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:228pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:409pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:424pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:453pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:469pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:279pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.91pt">*p &lt; 0.05</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 disease-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:67pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:413pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:67pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:425pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:425pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:425pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">19</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:67pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:413pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:67pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:87pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:67pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:86pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:86pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:101pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:101pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:101pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:101pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:101pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:128pt"><span style="font-family:Arial,sans-serif;font-size:9.547pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:222pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:240pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:253pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:325pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:384pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p&lt;0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p&lt;0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with psoriatic arthritis. Patients were between 18 and 70 years of age and had active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 swollen joints and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 tender joints) in at least one of the following forms: (1) distal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosis. Patients also had plaque psoriasis with a qualifying target lesion </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24%). Patients currently on methotrexate therapy (stable for </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 months) could continue at a stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 25 mg/week methotrexate. Doses of 25 mg of Enbrel (based on dose-finding studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. At the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">end of the double-blind study, patients could enter a long-term open-label extension study for a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarised in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 50</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">21</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  PsARC</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: 25 mg Enbrel SC twice weekly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p &lt; 0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: p &lt; 0.01, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients was assessed at every timepoint using the disability index of the HAQ. The disability index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relative to placebo (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the table below. In an analysis in which all patients who dropped out of the study for any reason were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered to have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively, p &#x2264; 0.001). The effect of Enbrel on radiographic progression was maintained in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who continued on treatment during the second year. The slowing of peripheral joint damage was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients with polyarticular symmetrical joint involvement.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Mean (SE) Annualized Change from Baseline in Total Sharp Score</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:154pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 104)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 101)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Month 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.00 (0.29)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.03 (0.09)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SE = standard error.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p = 0.0001.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit was maintained during the longer-term exposure of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis mutilans psoriatic arthropathies due to the small number of patients studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No study has been performed in patients with psoriatic arthritis using the 50 mg once-weekly dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">based on data from the study in patients with ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with ankylosing spondylitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing twice-weekly administration of 25 mg Enbrel with placebo. A total of 401 patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enrolled, from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visual analog scale (VAS) scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for average of duration and intensity of morning stiffness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plus VAS scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for at least 2 of the following 3 parameters: patient global assessment; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were not included in the study. Doses of 25 mg of Enbrel (based on dose-finding studies in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">138 patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary measure of efficacy (ASAS 20) was a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% improvement in at least 3 of the 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Ankylosing Spondylitis in a </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo-controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:161pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Ankylosing Spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:165pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:383pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p = 0.002, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. Responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar in patients who were or were not receiving concomitant therapies at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly vs. 25 mg Enbrel administered twice weekly were evaluated in a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled study of 356 patients with active ankylosing spondylitis. The safety and efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profiles of the 50 mg once-weekly and 25 mg twice-weekly regimens were similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 1</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meet the modified New York criteria for AS. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of the four ASAS domains and absence of deterioration in the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">domain. The double-blind period was followed by an open-label period during which all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive Enbrel 50 mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained to assess inflammation at baseline and at weeks 12 and 104.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission and BASDAI 50. Week 12 results are shown in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:90pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:273pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoints</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double-Blind Clinical</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Responses at Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=106 to 109*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=103 to 105*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS** 40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS partial remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI***50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*Some patients did not provide complete data for each endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**ASAS=Assessments in Spondyloarthritis International Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for placebo treated (n=105) patients (p&lt;0.001). At week 104, the mean change from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.40 the spine (n=154).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in most health-related quality of life and physical function assessments, including BASFI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physical Component Score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visit (2 weeks) and were maintained through 2 years of therapy. Improvements in health-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life and physical function were also maintained through 2 years of therapy. The 2 year data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">did not reveal any new safety findings. At week 104, 8 subjects had progressed to a score of bilateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthropathy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 2</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following 24 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">209 adult patients with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt; 3 mg/l), and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:773pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label Enbrel 50 mg weekly plus stable background NSAID at the optimal tolerated </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory dosage for 24 weeks in Period 1. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. At week 24, 119 (57%) patients achieved inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease and entered into the Period 2 40-week withdrawal phase where subjects discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept, yet maintained the background NSAID. The primary measure of efficacy was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 2.1) within 40 weeks following withdrawal of Enbrel. Patients who flared were retreated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg weekly for 12 weeks (Period 3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Period 2, the proportion of patients experiencing &#x2265;1 flare increased from 22% (25/112) at week 4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additionally compare the time to flare to patients from Study 1 who met the Study 2 withdrawal phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entry requirements and continued Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24 weeks). Less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 25% of patients in Study 1 who did not have treatment withdrawn experienced a flare over the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept treatment (Study 1), p&lt;0.0001.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 87 patients who entered Period 3 and were retreated with Enbrel 50 mg weekly for 12 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5 weeks (95% CI: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4-8 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% of the body surface area who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">25</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 and 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt; 0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drug and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received 0.4 mg/kg (maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four months and assessed for disease flare. Responses were measured using the ACR Pedi 30 , defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">core set criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrollment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:173pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">28</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beyond the 48 week study discussed above. Long-term experience with Enbrel was generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable to the original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products, as well as the parent compound.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean serum concentration profiles at steady state in treated RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. In an open-label, single-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N= 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Linearity</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">29</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">estimates in patients less than 65 years of age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice-weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol (E421)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trometamol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chemical and physical in-use stability has been demonstrated for 6 hours at temperatures of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C after reconstitution. From a microbiological point of view, the reconstituted medicinal product </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be used immediately. If not used immediately, storage times and conditions prior to use are the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responsibility of the user and would normally not be longer than 6 hours at temperatures of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C, unless reconstitution has taken place in controlled and validated aseptic conditions.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For storage conditions of the reconstituted medicinal product, see section 6.3.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear glass vial (2 ml, type I glass) with rubber stoppers, aluminium seals, and flip-off plastic caps. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 4 vials of Enbrel with 8 alcohol swabs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Instructions for use and handling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is reconstituted with 1 ml water for injections before use and administered by subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection. Enbrel contains no antibacterial preservative, and therefore, solutions prepared with water </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for injections should be administered as soon as possible and within 6 hours following reconstitution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The solution should be clear and colourless to pale yellow or pale brown, with no lumps, flakes or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">particles. Some white foam may remain in the vial &#x2013; this is normal. Enbrel should not be used if all the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">powder in the vial is not dissolved within 10 minutes. If this is the case, start again with another vial.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &#x201c;Instructions for preparation and giving an injection of Enbrel&#x201d;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">32</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg powder and solvent for solution for injection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each vial contains 25 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder and solvent for solution for injection (powder for injection).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The powder is white. The solvent is a clear, colourless liquid.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate (unless contraindicated), has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not previously treated with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage as measured by X-ray and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">33</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of active and progressive psoriatic arthritis in adults when the response to previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoralen and ultraviolet-A light (PUVA) (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis. Patients treated with Enbrel should be given the Patient Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is available in strengths of 10, 25 and 50 mg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly has been shown to be safe and effective (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For all of the above indications, available data suggest that a clinical response is usually achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responding within this time period.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">34</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No data are available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg vial strength may be more appropriate for administration to children with JIA below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight of 25 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is administered by subcutaneous injection. Enbrel powder for solution must be reconstituted in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 ml of solvent before use (see section 6.6).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">35</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &quot;Instructions for preparation and giving an injection of Enbrel.&quot;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">provided in section 3 of the package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections, including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location, have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The rubber tip cap (closure) of the diluent syringe contains latex (dry natural rubber) that may cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible latex sensitivity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">37</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving Enbrel were able to mount effective B-cell immune response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is unknown.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">38</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(DMARD) has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">41</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">42</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and parasitic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin cancers* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytope</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">nia, anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">antibody positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">optic neuritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">transverse myelitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">failure congestive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bowel disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">43</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">primarily palms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeleta</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">l and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including 231 patients treated with Enbrel in combination with methotrexate in the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study. The observed rates and incidences in these clinical trials were similar to those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">expected for the population studied. A total of 2 malignancies were reported in clinical studies of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection, along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Streptococcal</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">45</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients. Differences from adults and other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considerations are discussed in the following paragraphs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:770pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd"> Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biological activity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p &lt; 0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt; 3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses were escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial and continued for up to 24 months. Clinical improvement, including onset of action within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and was maintained for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.5. Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">48</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt;3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:78pt"><span style="font-family:Arial,sans-serif;font-size:9.847pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:398pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:369pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:405pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:458pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:138pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:155pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:184pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:229pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:409pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:425pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:453pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:470pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:279pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">*p &lt; 0.05</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:62pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:230pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:334pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:424pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:62pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:239pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:335pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:427pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:239pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:335pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:427pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:239pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:335pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:427pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">49</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:62pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:230pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:334pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:424pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:62pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:441pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:433pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:62pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:441pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:102pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:102pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:102pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:102pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:102pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:128pt"><span style="font-family:Arial,sans-serif;font-size:9.547pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:222pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:240pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:253pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:325pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:384pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p &lt; 0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p &lt; 0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with psoriatic arthritis. Patients were between 18 and 70 years of age and had active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 swollen joints and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 tender joints) in at least one of the following forms: (1) distal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosis. Patients also had plaque psoriasis with a qualifying target lesion </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24%). Patients currently on methotrexate therapy (stable for </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 months) could continue at a stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 25 mg/week methotrexate. Doses of 25 mg of Enbrel (based on dose-finding studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. At the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">end of the double-blind study, patients could enter a long-term open-label extension study for a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarised in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 50</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">51</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  PsARC</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: 25 mg Enbrel SC twice weekly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p &lt; 0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: p &lt; 0.01, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients was assessed at every timepoint using the disability index of the HAQ. The disability index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relative to placebo (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the table below. In an analysis in which all patients who dropped out of the study for any reason were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered to have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively, p &#x2264; 0.001). The effect of Enbrel on radiographic progression was maintained in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who continued on treatment during the second year. The slowing of peripheral joint damage was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients with polyarticular symmetrical joint involvement.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Mean (SE) Annualized Change from Baseline in Total Sharp Score</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:154pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 104)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 101)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Month 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.00 (0.29)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.03 (0.09)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SE = standard error.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p = 0.0001.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit was maintained during the longer-term exposure of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis mutilans psoriatic arthropathies due to the small number of patients studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No study has been performed in patients with psoriatic arthritis using the 50 mg once-weekly dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">based on data from the study in patients with ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with ankylosing spondylitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing twice-weekly administration of 25 mg Enbrel with placebo. A total of 401 patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enrolled, from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visual analog scale (VAS) scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for average of duration and intensity of morning stiffness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plus VAS scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for at least 2 of the following 3 parameters: patient global assessment; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were not included in the study. Doses of 25 mg of Enbrel (based on dose-finding studies in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">138 patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary measure of efficacy (ASAS 20) was a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% improvement in at least 3 of the 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Ankylosing Spondylitis in a </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo-controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:161pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Ankylosing Spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:165pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:383pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p&lt;0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p = 0.002, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. Responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar in patients who were or were not receiving concomitant therapies at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly vs. 25 mg Enbrel administered twice weekly were evaluated in a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled study of 356 patients with active ankylosing spondylitis. The safety and efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profiles of the 50 mg once-weekly and 25 mg twice-weekly regimens were similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 1</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meet the modified New York criteria for AS. Patients were also required to have an inadequate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">53</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of the four ASAS domains and absence of deterioration in the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">domain. The double-blind period was followed by an open-label period during which all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive Enbrel 50 mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained to assess inflammation at baseline and at weeks 12 and 104.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission and BASDAI 50. Week 12 results are shown in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:90pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:273pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoints</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double-Blind Clinical</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Responses at Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=106 to 109*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=103 to 105*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS** 40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS partial remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI***50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*Some patients did not provide complete data for each endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**ASAS=Assessments in Spondyloarthritis International Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for placebo treated (n=105) patients (p&lt;0.001). At week 104, the mean change from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.40 the spine (n=154).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in most health-related quality of life and physical function assessments, including BASFI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physical Component Score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visit (2 weeks) and were maintained through 2 years of therapy. Improvements in health-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life and physical function were also maintained through 2 years of therapy. The 2 year data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">did not reveal any new safety findings. At week 104, 8 subjects had progressed to a score of bilateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthropathy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 2</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following 24 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">209 adult patients with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt;3 mg/l), and active symptoms </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">54</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg weekly plus stable background NSAID at the optimal tolerated anti-inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dosage for 24 weeks in Period 1. Patients were also required to have an inadequate response or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intolerance to two or more NSAIDs. At week 24, 119 (57%) patients achieved inactive disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entered into the Period 2 40-week withdrawal phase where subjects discontinued etanercept, yet </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained the background NSAID. The primary measure of efficacy was the occurrence of flare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal to 2.1) within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. Patients who flared were retreated with Enbrel 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly for 12 weeks (Period 3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Period 2, the proportion of patients experiencing &#x2265;1 flare increased from 22% (25/112) at week 4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additionally compare the time to flare to patients from Study 1 who met the Study 2 withdrawal phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entry requirements and continued Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24 weeks). Less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 25% of patients in Study 1 who did not have treatment withdrawn experienced a flare over the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept treatment (Study 1), p &lt; 0.0001.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 87 patients who entered Period 3 and were retreated with Enbrel 50 mg weekly for 12 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5 weeks (95% CI: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4-8 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10% of the body surface area who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 and 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">56</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8 % of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with polyarticular-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to severely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were enrolled; patients remained on a stable dose of a single nonsteroidal anti-inflammatory drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients received 0.4 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, patients with a clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at day 90 were randomised to remain on Enbrel or receive placebo for four months and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed for disease flare. Responses were measured using ACR Pedi 30 , defined as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA core set </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrollment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">58</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beyond the 48 week study discussed above. Long-term experience with Enbrel was generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable to the original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products, as well as the parent compound.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean serum concentration profiles at steady state in treated RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. In an open-label, single-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N= 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Linearity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">estimates in patients less than 65 years of age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice-weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol (E421)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trometamol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solvent</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chemical and physical in-use stability has been demonstrated for 6 hours at temperatures of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C after reconstitution. From a microbiological point of view, the reconstituted medicinal product </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be used immediately. If not used immediately, storage times and conditions prior to use are the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responsibility of the user and would normally not be longer than 6 hours at temperatures of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C, unless reconstitution has taken place in controlled and validated aseptic conditions.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C - 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For storage conditions of the reconstituted medicinal product, see section 6.3.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear glass vial (2 ml, type I glass) with rubber stoppers, aluminium seals, and flip-off plastic caps. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is supplied with pre-filled syringes containing water for injection. The syringes are type I glass.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The syringe cover contains dry natural rubber (latex) (see section 4.4). Cartons contain 4, 8 or 24 vials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel with 4, 8 or 24 pre-filled solvent syringes, 4, 8 or 24 needles, 4, 8 or 24 vial adaptors and 8, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 or 48 alcohol swabs. Not all pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Instructions for use and handling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection. Enbrel contains no antibacterial preservative, and therefore, solutions prepared with water </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for injections should be administered as soon as possible and within 6 hours following reconstitution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The solution should be clear and colourless to pale yellow or pale brown, with no lumps, flakes or </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">61</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">particles. Some white foam may remain in the vial &#x2013; this is normal. Enbrel should not be used if all the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">powder in the vial is not dissolved within 10 minutes. If this is the case, start again with another vial.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &#x201c;Instructions for preparation and giving an injection of Enbrel&#x201d;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">62</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each pre-filled syringe contains 25 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each pre-filled syringe contains 50 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The solution is clear, and colourless to pale yellow or pale brown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate (unless contraindicated), has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not previously treated with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage as measured by X-ray and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoralen and ultraviolet-A light (PUVA) (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis. Patients treated with Enbrel should be given the Patient Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is available in strengths of 10, 25 and 50 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly has been shown to be safe and effective (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For all of the above indications, available data suggest that a clinical response is usually achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responding within this time period.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than 62.5 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be accurately dosed on a mg/kg basis using the powder and solvent for solution for injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presentations or the powder for solution for injection presentations (see below for dosing for specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications). Patients weighing 62.5 kg or more, may be dosed using a fixed-dose pre-filled syringe or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-filled pen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No data are available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg vial strength may be more appropriate for administration to children with JIA below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight of 25 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">65</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is administered by subcutaneous injection (see section 6.6).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for administration are given in the package leaflet, section 7, &quot;Instructions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for preparation and giving an injection of Enbrel.&quot; Detailed instructions on unintentional dosing or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scheduling variations, including missed doses, are provided in section 3 of the package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections, including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location, have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">66</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The needle cover of the pre-filled syringe contains latex (dry natural rubber) that may cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible latex sensitivity.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">67</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">68</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving Enbrel were able to mount effective B-cell immune response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(DMARD) has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">69</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium content</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit. Patients on low </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sodium diets can be informed that this medicinal product is essentially &#x2018;sodium-free&#x2019;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">72</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and parasitic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin cancers* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytope</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">nia, anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">antibody positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">optic neuritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">transverse myelitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">failure congestive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bowel disease</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">73</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">primarily palms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeleta</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">l and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including 231 patients treated with Enbrel in combination with methotrexate in the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study. The observed rates and incidences in these clinical trials were similar to those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">expected for the population studied. A total of 2 malignancies were reported in clinical studies of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">74</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection, along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Streptococcal</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients. Differences from adults and other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considerations are discussed in the following paragraphs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">76</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biological activity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses were escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial and continued for up to 24 months. Clinical improvement, including onset of action within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and was maintained for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.5. Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">78</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt;3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:78pt"><span style="font-family:Arial,sans-serif;font-size:9.847pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:398pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:369pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:405pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:458pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:138pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:155pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:184pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:229pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:409pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:425pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:453pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:470pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:279pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">*p &lt; 0.05</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:83pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:84pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:193pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:419pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">79</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:83pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:84pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:193pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:419pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:431pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:427pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:302pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:424pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:431pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:427pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:136pt"><span style="font-family:Arial,sans-serif;font-size:8.992pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:161pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:161pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:163pt"><span style="font-family:Arial,sans-serif;font-size:7.492pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:365pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:365pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:226pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:243pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:255pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:324pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:381pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:394pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.492pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:237pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:10.492pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:10.492pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:376pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:10.492pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p&lt; 0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p&lt; 0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with psoriatic arthritis. Patients were between 18 and 70 years of age and had active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 swollen joints and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 tender joints) in at least one of the following forms: (1) distal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosis. Patients also had plaque psoriasis with a qualifying target lesion </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24%). Patients currently on methotrexate therapy (stable for </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 months) could continue at a stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 25 mg/week methotrexate. Doses of 25 mg of Enbrel (based on dose-finding studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. At the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">end of the double-blind study, patients could enter a long-term open-label extension study for a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarised in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 50</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  PsARC</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">81</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: 25 mg Enbrel SC twice weekly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p &lt; 0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: p &lt; 0.01, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients was assessed at every timepoint using the disability index of the HAQ. The disability index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relative to placebo (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the table below. In an analysis in which all patients who dropped out of the study for any reason were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered to have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively, p &#x2264; 0.001). The effect of Enbrel on radiographic progression was maintained in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who continued on treatment during the second year. The slowing of peripheral joint damage was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients with polyarticular symmetrical joint involvement.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Mean (SE) Annualized Change from Baseline in Total Sharp Score</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:154pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 104)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 101)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Month 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.00 (0.29)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.03 (0.09)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SE = standard error.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p = 0.0001.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit was maintained during the longer-term exposure of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis mutilans psoriatic arthropathies due to the small number of patients studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No study has been performed in patients with psoriatic arthritis using the 50 mg once-weekly dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">based on data from the study in patients with ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with ankylosing spondylitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing twice-weekly administration of 25 mg Enbrel with placebo. A total of 401 patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enrolled, from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visual analog scale (VAS) scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for average of duration and intensity of morning stiffness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plus VAS scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for at least 2 of the following 3 parameters: patient global assessment; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were not included in the study. Doses of 25 mg of Enbrel (based on dose-finding studies in patients </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">82</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">138 patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary measure of efficacy (ASAS 20) was a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% improvement in at least 3 of the 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Ankylosing Spondylitis in a </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo-controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:161pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Ankylosing Spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:165pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:383pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p = 0.002, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. Responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar in patients who were or were not receiving concomitant therapies at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly vs. 25 mg Enbrel administered twice weekly were evaluated in a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled study of 356 patients with active ankylosing spondylitis. The safety and efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profiles of the 50 mg once-weekly and 25 mg twice-weekly regimens were similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 1</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meet the modified New York criteria for AS. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of the four ASAS domains and absence of deterioration in the remaining </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">domain. The double-blind period was followed by an open-label period during which all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive Enbrel 50 mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained to assess inflammation at baseline and at weeks 12 and 104.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission and BASDAI 50. Week 12 results are shown in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:90pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:273pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoints</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double-Blind Clinical</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Responses at Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=106 to 109*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=103 to 105*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS** 40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS partial remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI***50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*Some patients did not provide complete data for each endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**ASAS=Assessments in Spondyloarthritis International Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for placebo treated (n=105) patients (p&lt;0.001). At week 104, the mean change from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.40 the spine (n=154).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in most health-related quality of life and physical function assessments, including BASFI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physical Component Score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visit (2 weeks) and were maintained through 2 years of therapy. Improvements in health-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life and physical function were also maintained through 2 years of therapy. The 2 year data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">did not reveal any new safety findings. At week 104, 8 subjects had progressed to a score of bilateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthropathy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 2</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following 24 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">209 adult patients with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt;3 mg/l), and active symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg weekly plus stable background NSAID at the optimal tolerated anti-inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dosage for 24 weeks in Period 1. Patients were also required to have an inadequate response or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intolerance to two or more NSAIDs. At week 24, 119 (57%) patients achieved inactive disease and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entered into the Period 2 40-week withdrawal phase where subjects discontinued etanercept, yet </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained the background NSAID. The primary measure of efficacy was the occurrence of flare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal to 2.1) within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. Patients who flared were retreated with Enbrel 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly for 12 weeks (Period 3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Period 2, the proportion of patients experiencing &#x2265;1 flare increased from 22% (25/112) at week 4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additionally compare the time to flare to patients from Study 1 who met the Study 2 withdrawal phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entry requirements and continued Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24 weeks). Less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 25% of patients in Study 1 who did not have treatment withdrawn experienced a flare over the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept treatment (Study 1), p&lt;0.0001.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 87 patients who entered Period 3 and were retreated with Enbrel 50 mg weekly for 12 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5 weeks (95% CI: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4-8 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% of the body surface area who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">85</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p &lt; 0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 and 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt; 0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">86</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drug and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received 0.4 mg/kg (maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">core set criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrolment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">87</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">88</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years beyond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the 48 week study discussed above. Long-term experience with Enbrel was generally comparable to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products, as well as the parent compound.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean serum concentration profiles at steady state in treated RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. In an open-label, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">single-dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N = 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Linearity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">89</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">estimates in patients less than 65 years of age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice-weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium chloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">L-Arginine hydrochloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate monobasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate dibasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C - 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Keep the pre-filled syringes in the outer carton in order to protect from light.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear glass syringe (type I glass) with stainless steel needle, rubber needle cover and plastic plunger.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 4, 8, 12 or 24 pre-filled syringes of Enbrel and 4, 8, 12 or 24 alcohol swabs. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needle cover contains dry natural rubber (latex) (see section 4.4). Not all pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear glass syringe (type I glass) with stainless steel needle, rubber needle cover and plastic plunger. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 2, 4 or 12 pre-filled syringes of Enbrel with 2, 4 or 12 alcohol swabs. The needle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cover contains dry natural rubber (latex) (see section 4.4). Not all pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before injection, Enbrel single-use pre-filled syringe should be allowed to reach room temperature </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(approximately 15 to 30 minutes). The needle cover should not be removed while allowing the pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">filled syringe to reach room temperature. The solution should be clear to slightly opalescent,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colourless to pale yellow or pale brown and may contain small translucent or white particles of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">protein. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for administration are given in the package leaflet, section 7, &quot;Instructions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for preparation and giving an injection of Enbrel.&quot;</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">91</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/014</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/026</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/016</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/017</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/018</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">92</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each pre-filled pen contains 25 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each pre-filled pen contains 50 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The solution is clear, and colourless to pale yellow or pale brown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate (unless contraindicated), has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not previously treated with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage as measured by X-ray and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">93</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of active and progressive psoriatic arthritis in adults when the response to previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoralen and ultraviolet-A light (PUVA) (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis. Patients treated with Enbrel should be given the Patient Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The Enbrel pre-filled pen is available in 25 mg and 50 mg strengths. Other presentations of Enbrel are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">available in strengths of 10 mg, 25 mg, and 50 mg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly has been shown to be safe and effective (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">94</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For all of the above indications, available data suggest that a clinical response is usually achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.5 kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection presentations or the powder for solution for injection presentations (see below for dosing for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">specific indication). Patients weighing 62.5 kg or more, may be dosed using a fixed-dose pre-filled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe or pre-filled pen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No data are available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg vial strength may be more appropriate for administration to children with JIA below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight of 25 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">95</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is administered by subcutaneous injection (see section 6.6).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for administration are given in the package leaflet, section 7, &#x201c;Using the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MYCLIC pre-filled pen to inject Enbrel.&#x201d; Detailed instructions on unintentional dosing or scheduling </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">variations, including missed doses, are provided in section 3 of the package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The needle cap of the pre-filled pen contains latex (dry natural rubber) that may cause hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions when handled by or when Enbrel is administered to persons with known or possible latex </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sensitivity. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">97</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double blind, placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a multivalent pneumococcal polysaccharide vaccine at week 4. In this study most psoriatic arthritis </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">98</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polysaccharide vaccine, but titres in aggregate were moderately lower and few patients had two-fold </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rises in titres compared to patients not receiving Enbrel. The clinical significance of this is unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(DMARD) has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">99</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium content</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit. Patients on low </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sodium diets can be informed that this medicinal product is essentially &#x2018;sodium-free&#x2019;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">102</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to &lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">parasitic infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">viral infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cancers* (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">melanoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">positive vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphyla</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">ctic reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">as optic neuritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and transverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">myelitis (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and multifocal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">103</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:69pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to &lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:339pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:466pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory bowel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, primarily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">palms and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeleta</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">l and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:69pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine new malignancies of various types were observed in 4,114 rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">231 patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study. The observed rates and incidences in these clinical trials were similar to those expected for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">population studied. A total of 2 malignancies were reported in clinical studies of approximately 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical studies conducted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients. Differences from adults and other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considerations are discussed in the following paragraphs.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">106</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells including T-cells leads to increased TNF levels in psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF-binding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to its cell surface receptors and thereby inhibits the biological activity of TNF. TNF and lymphotoxin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors such as etanercept possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p &lt; 0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered SC twice a week for up to 24 months. Methotrexate doses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the trial and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued for up to 24 months. Clinical improvement including onset of action within 2 weeks with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg was similar to that seen in the previous trials, and was maintained for up to 24 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt;3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:78pt"><span style="font-family:Arial,sans-serif;font-size:9.847pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:398pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:369pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:405pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:458pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:138pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:155pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:184pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:229pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:409pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:425pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:453pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:470pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:279pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">*p &lt; 0.05</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and of the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:68pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs Methotrexate vs Enbrel in </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:442pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:229pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:442pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:128pt"><span style="font-family:Arial,sans-serif;font-size:9.547pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:222pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:240pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:253pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:325pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:384pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p&lt; 0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p&lt; 0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens. A single 50 mg/ml injection of Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with psoriatic arthritis. Patients were between 18 and 70 years of age and had active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 swollen joints and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 tender joints) in at least one of the following forms: (1) distal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosis. Patients also had plaque psoriasis with a qualifying target lesion </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24%). Patients currently on methotrexate therapy (stable for </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 months) could continue at a stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 25 mg/week methotrexate. Doses of 25 mg of Enbrel (based on dose-finding studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. At the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">end of the double-blind study, patients could enter a long-term open-label extension study for a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarised in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 50</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  PsARC</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: 25 mg Enbrel SC twice weekly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p &lt; 0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: p &lt; 0.01, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients was assessed at every timepoint using the disability index of the HAQ. The disability index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relative to placebo (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Table below. In an analysis in which all patients who dropped out of the study for any reason were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered to have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively, p &#x2264; 0.001). The effect of Enbrel on radiographic progression was maintained in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who continued on treatment during the second year. The slowing of peripheral joint damage was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients with polyarticular symmetrical joint involvement.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Mean (SE) Annualized Change from Baseline in Total Sharp Score</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:154pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 104)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 101)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Month 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.00 (0.29)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.03 (0.09)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SE = standard error.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p = 0.0001.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit was maintained during the longer-term exposure of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis mutilans psoriatic arthropathies due to the small number of patients studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No study has been performed in patients with psoriatic arthritis using the 50 mg once weekly dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen. Evidence of efficacy for the once weekly dosing regimen in this patient population has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">based on data from the study in patients with ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with ankylosing spondylitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing twice weekly administration of 25 mg Enbrel with placebo. A total of 401 patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enrolled from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visual analog scale (VAS) scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for average of duration and intensity of morning stiffness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plus VAS scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for at least 2 of the following 3 parameters: patient global assessment; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">112</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were not included in the study. Doses of 25 mg of Enbrel (based on dose-finding studies in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">138 patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary measure of efficacy (ASAS 20) was a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 20% improvement in at least 3 of the 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Ankylosing Spondylitis in a </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:238pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo-Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:161pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Ankylosing Spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:165pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:383pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 70:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, Enbrel vs. Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p = 0.002, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. Responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar in patients who were or were not receiving concomitant therapies at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly vs 25 mg Enbrel administered twice weekly were evaluated in a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled study of 356 patients with active ankylosing spondylitis. The safety and efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profiles of the 50 mg once weekly and 25 mg twice weekly regimens were similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 1</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meet the modified New York criteria for AS. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of the four ASAS domains and absence of deterioration in the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">domain. The double-blind period was followed by an open-label period during which all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive Enbrel 50 mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained to assess inflammation at baseline and at weeks 12 and 104.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission and BASDAI 50. Week 12 results are shown in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoints</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double-Blind Clinical</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Responses at Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=106 to 109*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=103 to 105*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS** 40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS partial remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI***50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*Some patients did not provide complete data for each endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**ASAS=Assessments in Spondyloarthritis International Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for placebo treated (n=105) patients (p&lt;0.001). At week 104, the mean change from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.40 the spine (n=154).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in most health-related quality of life and physical function assessments, including BASFI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physical Component Score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visit (2 weeks) and were maintained through 2 years of therapy. Improvements in health-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life and physical function were also maintained through 2 years of therapy. The 2 year data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">did not reveal any new safety findings. At week 104, 8 subjects had progressed to a score of bilateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthropathy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 2</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following 24 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">209 adult patients with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">114</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt; 3 mg/l), and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label Enbrel 50 mg weekly plus stable background NSAID at the optimal tolerated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory dosage for 24 weeks in Period 1. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. At week 24, 119 (57%) patients achieved inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease and entered into the Period 2 40-week withdrawal phase where subjects discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept, yet maintained the background NSAID. The primary measure of efficacy was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 2.1) within 40 weeks following withdrawal of Enbrel. Patients who flared were retreated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg weekly for 12 weeks (Period 3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Period 2, the proportion of patients experiencing &#x2265;1 flare increased from 22% (25/112) at week 4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additionally compare the time to flare to patients from Study 1 who met the Study 2 withdrawal phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entry requirements and continued Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24 weeks). Less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 25% of patients in Study 1 who did not have treatment withdrawn experienced a flare over the</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept treatment (Study 1), p&lt;0.0001.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 87 patients who entered Period 3 and were retreated with Enbrel 50 mg weekly for 12 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5 weeks (95% CI: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4-8 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt; 50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% of the body surface area that were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt; 0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:173pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 And 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">------------------Study 2--------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:196pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">---------------Study 3------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:340pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">---------------Study 4------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">116</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drug and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received 0.4 mg/kg (maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">core set criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">117</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrolment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g. PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">118</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:77pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beyond the 48 week study discussed above. Long-term experience with Enbrel was generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable to the original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products as well as the parent compound.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean serum concentration profiles at steady state in treated RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. In an open-label, single-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N = 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">119</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Linearity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">estimates in patients less than 65 years of age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">120</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium chloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">L-Arginine hydrochloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate monobasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate dibasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Keep the pre-filled pens in the outer carton in order to protect from light.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pre-filled pen (MYCLIC) containing a 25 mg pre-filled syringe of Enbrel. The syringe inside the pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plunger. The needle cap of the pre-filled pen contains dry natural rubber (a derivative of latex). See </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 4, 8 or 24 pre-filled pens of Enbrel with 4, 8 or 24 alcohol swabs. Not all pack sizes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pre-filled pen (MYCLIC) containing a 50 mg pre-filled syringe of Enbrel. The syringe inside the pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">121</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plunger. The needle cap of the pre-filled pen contains dry natural rubber (a derivative of latex). See </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 2, 4 or 12 pre-filled pens of Enbrel with 2, 4 or 12 alcohol swabs. Not all pack sizes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Instructions for use and handling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before injection, Enbrel single-use pre-filled pens should be allowed to reach room temperature </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(approximately 15 to 30 minutes). The needle cover should not be removed while allowing the pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">filled pen to reach room temperature. By looking through the inspection window, the solution should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be clear to slightly opalescent, colourless to pale yellow or pale brown and may contain small </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">translucent or white particles of protein. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for administration are given in the package leaflet, section 7, &quot;Using the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MYCLIC pre-filled pen to inject Enbrel.&quot;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/023</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/024</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/025</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/019</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/021</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 10 mg powder and solvent for solution for injection for paediatric use</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each vial contains 10 mg of etanercept. When reconstituted, the solution contains 10 mg/ml of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder and solvent for solution for injection (powder for injection).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The powder is white. The solvent is a clear, colourless liquid.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of juvenile idiopathic arthritis or paediatric plaque psoriasis. Patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel should be given the Patient Card.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">123</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Special populations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg presentation is for paediatric patients prescribed a dose of 10 mg or less. Each vial of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg should be used on a single occasion in a single patient, and the remainder of the vial should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discarded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is administered by subcutaneous injection. Enbrel powder for solution must be reconstituted in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 ml of solvent before use (see section 6.6).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &quot;Instructions for preparation and giving an injection of Enbrel.&quot;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">provided in section 3 of the package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections, including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">124</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location, have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">125</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The rubber tip cap (closure) of the diluent syringe contains latex (dry natural rubber) that may cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible latex sensitivity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">126</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving Enbrel were able to mount effective B-cell immune response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">127</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in adult rheumatoid arthritis patients, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of Enbrel and methotrexate did not result in unexpected safety findings, and the safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of Enbrel when given in combination with methotrexate was similar to the profiles reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies of Enbrel and methotrexate alone. Long-term studies to assess the safety of the combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are ongoing. The long-term safety of Enbrel in combination with other disease-modifying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antirheumatic drugs (DMARD) has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">128</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">129</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">130</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients (see below, Undesirable effects in adults). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Differences from adults and other special considerations are discussed in the following paragraphs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Undesirable effects in adults</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">131</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to &lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">parasitic infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">viral infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cancers* (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">melanoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">&#x2020;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">positive vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphyla</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">ctic reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:464pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">132</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to &lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">as optic neuritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and transverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">myelitis (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and multifocal</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory bowel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, primarily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">palms and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeleta</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">l and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">133</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:66pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:134pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:188pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to &lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:464pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:134pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:66pt"><span style="font-family:TimesNewRoman,serif;font-size:6pt">&#x2020;</span><span style="font-family:TimesNewRoman,serif;font-size:9pt">Please see sub-section &#x2018;Undesirable effects in paediatric patients with juvenile idiopathic arthritis&#x2019; above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including 231 patients treated with Enbrel in combination with methotrexate in the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study. The observed rates and incidences in these clinical trials were similar to those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">expected for the population studied. A total of 2 malignancies were reported in clinical studies of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection, along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">134</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Streptococcal</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">135</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Summary of the safety profile, above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">136</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biological activity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from three studies in juvenile idiopathic arthritis, one study in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis, four studies in adults with rheumatoid arthritis, and four studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drug and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received 0.4 mg/kg (maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">core set criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">137</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrolment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:77pt;left:173pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years beyond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the 48 week study discussed above. Long-term experience with Enbrel was generally comparable to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt; 3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses were escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial and continued for up to 24 months. Clinical improvement, including onset of action within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and was maintained for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.5. Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt; 3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:79pt"><span style="font-family:Arial,sans-serif;font-size:9.735pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:323pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.817pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:369pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:406pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:459pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.735pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:139pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:155pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:184pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:229pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:365pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:381pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:410pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:426pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:454pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:471pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:280pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.767pt">*p &lt; 0.05</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 disease-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:96pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs. Methotrexate vs. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel in Combination with Methotrexate in Patients with RA of 6 Months To </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:247pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:92pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:413pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:409pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:92pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:213pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:213pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:213pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:412pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:92pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:220pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:425pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:220pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:111pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:217pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:92pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:110pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:220pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:425pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:110pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:220pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:128pt"><span style="font-family:Arial,sans-serif;font-size:9.547pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.95pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:222pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:240pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:253pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:325pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:384pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.95pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.36pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.36pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.36pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">141</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p&lt;0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p&lt;0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% of the body surface area who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">142</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 and 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">143</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products as well as the parent compound.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">144</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice-weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adults</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Absorption</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml. Mean serum concentration profiles at steady state in treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. 2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">297 mgh/l vs. 316 mgh/l for 50 mg Enbrel once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. In an open-label, single-dose, two-treatment, crossover study in healthy volunteers, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept administered as a single 50 mg/ml injection was found to be bioequivalent to two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N= 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Distribution</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elimination</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Linearity</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">145</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol (E421)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trometamol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solvent</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">From a microbiological point of view, the reconstituted medicinal product should be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately. Chemical and physical in-use stability has been demonstrated for 6 hours at temperatures </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not above 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C after reconstitution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C - 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For storage conditions of the reconstituted medicinal product, see section 6.3.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear glass vial (2 ml, type I glass) with rubber stopper, aluminium seal, and flip-off plastic cap. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is supplied with pre-filled syringes containing water for injection. The syringes are type I glass.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The syringe cover contains dry natural rubber (latex) (see section 4.4). Cartons contain 4 vials of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, 4 pre-filled syringes of water for injections, 4 needles, 4 vial adaptors and 8 alcohol swabs.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Instructions for use and handling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection. The solution should be clear and colourless to pale yellow or pale brown, with no lumps, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flakes or particles. Some white foam may remain in the vial &#x2013; this is normal. Enbrel should not be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used if all the powder in the vial is not dissolved within 10 minutes. Start again with another vial.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given in the package leaflet, section 7, &quot;Instructions for preparation and giving an injection of Enbrel&quot;.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">146</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/022</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd"> http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">147</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each dose-dispenser cartridge contains 25 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each dose-dispenser cartridge contains 50 mg of etanercept.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The solution is clear, and colourless to pale yellow or pale brown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate (unless contraindicated), has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not previously treated with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage as measured by X-ray and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">children and adolescents from the age of 2 years who have had an inadequate response to, or who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proved intolerant of, methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to, or who have proved intolerant of, methotrexate.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">148</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or who have proved intolerant of, conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of active and progressive psoriatic arthritis in adults when the response to previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoralen and ultraviolet-A light (PUVA) (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis. Patients treated with Enbrel should be given the Patient Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The Enbrel dose-dispenser cartridge is available in 25 mg and 50 mg strengths. Other presentations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel are available in strengths of 10 mg, 25 mg, and 50 mg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly has been shown to be safe and effective (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">149</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For all of the above indications, available data suggest that a clinical response is usually achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.5 kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection presentations or the powder for solution for injection presentations (see below for dosing for</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">specific indication). Patients weighing 62.5 kg or more, may be dosed using a fixed-dose pre-filled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe , pre-filled pen, or dose-dispenser cartridge.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No data are available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:71pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who show no response after 4 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The 10 mg vial strength may be more appropriate for administration to children with JIA below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight of 25 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis (age 6 years and above)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">150</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Subcutaneous use</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The total content (0.5 ml for the 25 mg dose strength or 1 ml for the 50 mg dose strength) of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-dispenser cartridge should be administered using the SMARTCLIC injection device for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous injection only. Suitable sites for injection would include the abdomen, upper thighs, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">by caregiver only in the outer area of the upper arms.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel solution for injection in a dose-dispenser cartridge is intended for single-use in conjunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with the SMARTCLIC device. After proper training on the injection technique, patients may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">self-inject using the SMARTCLIC device with the single-use dose-dispenser cartridge if their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physician determines that it is appropriate and will receive medical follow-up as necessary. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physician should discuss with the patient which injection presentation option is the most appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For administration, the instructions for use at the end of the Package Leaflet and in the user manual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">provided with the SMARTCLIC device should be followed (see section 6.6). Detailed instructions on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unintentional dosing or scheduling variations, including missed doses, are provided in section 3 of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">package leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sepsis or risk of sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the brand name and batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">number of the administered product should be clearly recorded (or stated) in the patient file.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">300 hours).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In some cases, particular fungal and other opportunistic infections have not been recognised, resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient&#x2019;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should exercise caution when considering the use of Enbrel in patients with a history of recurring or </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic infections or with underlying conditions that may predispose patients to infections such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or poorly controlled diabetes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extra-pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">location have been reported in patients treated with Enbrel.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&#x2018;latent&#x2019;) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previously infected with HBV. These patients should be monitored for signs and symptoms of active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HBV infection throughout therapy and for several weeks following termination of therapy. Adequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from treating patients infected with HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of hepatitis C</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used with caution in patients with a history of hepatitis C.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and neutropenia compared to Enbrel alone. This combination has not demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased clinical benefit. Thus the combined use of Enbrel and anakinra is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.5 and 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.5).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">152</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions have included angioedema and urticaria; serious reactions have occurred. If any serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The needle cap of the dose-dispenser cartridge contains latex (dry natural rubber) that may cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypersensitivity reactions when handled by, or when Enbrel is administered to persons with known or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible latex sensitivity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The needle cover of the pre-filled syringe in dose-dispenser cartridge contains latex (dry natural </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rubber). Patients or caregivers should contact their physician or healthcare professional before using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel if the needle cover will be handled by or if Enbrel will be given to someone with a known or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible hypersensitivity (allergy) to latex.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector cell populations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Varicella Zoster Immune Globulin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Solid and haematopoietic malignancies (excluding skin cancers)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed among patients receiving a TNF-antagonist compared with control patients. However, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence was rare, and the follow-up period of placebo patients was shorter than for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates risk estimation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Caution should be exercised when considering TNF-antagonist therapy for patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy or when considering continuing treatment in patients who develop a malignancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies typically associated </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with TNF-antagonists cannot be excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Skin cancers</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients, particularly those with risk factors for skin cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel compared with control patients, particularly in patients with psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">transmission of infection by live vaccines in patients receiving Enbrel. In a double blind, placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a multivalent pneumococcal polysaccharide vaccine at week 4. In this study most psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polysaccharide vaccine, but titres in aggregate were moderately lower and few patients had two-fold </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rises in titres compared to patients not receiving Enbrel. The clinical significance of this is unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoantibody formation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients treated with Enbrel. Caution should be exercised in patients being treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should seek immediate medical advice. Such patients should be investigated urgently, including full </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinating polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to have an increased risk of developing demyelinating disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Combination therapy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(DMARD) has not been established.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis has not been studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or hepatic impairment; clinical experience in such patients is limited.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (Cardiac failure congestive)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of worsening of CHF, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">precipitating factors, in patients taking Enbrel. There have also been rare (&lt; 0.1%) reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">these patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to Enbrel treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alcoholic hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients who also have moderate to severe alcoholic hepatitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wegener&apos;s granulomatosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 months, has not shown Enbrel to be an effective treatment for Wegener&#x2019;s granulomatosis. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of non-cutaneous malignancies of various types was significantly higher in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">granulomatosis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoglycaemia in patients treated for diabetes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences in adverse events, serious adverse events, and serious infections in patients age 65 or older </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received Enbrel were observed compared with younger patients. However, caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised when treating the elderly and particular attention paid with respect to occurrence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">155</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric population</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Vaccinations</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">above).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium content</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit. Patients on low </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sodium diets can be informed that this medicinal product is essentially &#x2018;sodium-free&#x2019;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, in a double-blind placebo-controlled trial in adult patients receiving background </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of serious adverse events. This combination has not demonstrated increased clinical benefit; such use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with sulfasalazine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel was added, patients in the combination group experienced a statistically significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical significance of this interaction is unknown. Physicians should use caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy with sulfasalazine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-interactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In clinical trials, no interactions have been observed when Enbrel was administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analgesics, or methotrexate. See section 4.4 for vaccination advice.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, digoxin or warfarin.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of appropriate contraception to avoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">156</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigated in two observational cohort studies. A higher rate of major birth defects was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one observational study comparing pregnancies exposed to etanercept (n=370) during the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in the general population and no particular pattern of abnormalities was identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">another observational multi-country registry study comparing the risk of adverse pregnancy outcomes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at increased risk of infection. Administration of live vaccines to infants for 16 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother&#x2019;s last dose of Enbrel is generally not recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in the serum of pups. Limited information from the published literature indicates etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">has been detected at low levels in human milk. Etanercept could be considered for use during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for the woman.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier timepoint if the infant etanercept serum levels are undetectable).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and general reproductive performance are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel has no or negligible influence on the ability to drive and use machines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchitis, bladder infections and skin infections), headache, allergic reactions, development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibodies, itching, and fever.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">157</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the immune system and their use may affect the body&#x2019;s defenses against infection and cancer. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life-threatening infections and sepsis. Various malignancies have also been reported with use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been rare reports of lupus, lupus-related conditions, and vasculitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">postmarketing experience.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Within the organ system classes, adverse reactions are listed under headings of frequency (number of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients expected to experience the reaction), using the following categories: very common (&#x2265; 1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">common (&#x2265; 1/100 to &lt; 1/10); uncommon (&#x2265; 1/1,000 to &lt; 1/100); rare (&#x2265; 1/10,000 to &lt; 1/1,000); very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infestations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tract </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cystitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cellulitis, arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bacterial, sepsis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and parasitic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Tuberculosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infection (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">protozoal, bacterial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mycobacterial, viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">infections, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Legionella)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactivation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">listeria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Neoplasms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">malignant and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including cysts </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and polyps)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Non-melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">skin cancers* (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Malignant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">melanoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">carcinoma (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Kaposi&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Blood and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Thrombocytopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">leukopenia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutropenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pancytopenia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Aplastic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">anaemia*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Histiocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">haematophagic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(macrophage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">activation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Immune system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">autoantibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">formation*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neutrophilic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cytoplasmic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">antibody positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">allergic/anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bronchospasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">sarcoidosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">dermatomyositis</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">158</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">System Organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Common</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/100 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:190pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Uncommon</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/1,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&#x2265; 1/10,000 to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:331pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/1,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Very </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Rare</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:417pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">&lt; 1/10,000</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">(Cannot be </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Estimated </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Available </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:467pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:9pt">Data)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">CNS demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events suggestive of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiple sclerosis or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">localised</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">conditions, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">optic neuritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">transverse myelitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">events, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Guillain-Barr&#xe9; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">polyneuropathy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">neuropathy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4), seizure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Eye disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Uveitis, scleritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cardiac failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">congestive (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">New onset cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">failure congestive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(see section 4.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Respiratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">thoracic, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">mediastinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pneumonitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pulmonary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">fibrosis)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bowel disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Hepatobiliary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Elevated liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">enzymes*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hepatitis*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pruritus, rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Angioedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">worsening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pustular, primarily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">palms and soles), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">urticaria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">psoriasiform rash</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Stevens-Johnson </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">syndrome, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">cutaneous vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">vasculitis), erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">multiforme, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lichenoid reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">necrolysis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Musculoskeletal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">and connective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Cutaneous lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">subacute cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythematosus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">lupus-like syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">General </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bleeding, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">bruising, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">itching, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">swelling)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:190pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">Pyrexia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt">*see Description of selected adverse reactions, below.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">159</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred and twenty-nine new malignancies of various types were observed in 4,114 rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">231 patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study. The observed rates and incidences in these clinical trials were similar to those expected for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">population studied. A total of 2 malignancies were reported in clinical studies of approximately 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical studies conducted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received in the postmarketing period (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions in the Enbrel treatment groups, and the majority of patients who were given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment received topical preparations such as corticosteroids, or oral antihistamines. Additionally, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some patients developed recall injection site reactions characterised by a skin reaction at the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recent site of injection along with the simultaneous appearance of injection site reactions at previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection sites. These reactions were generally transient and did not recur with treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rheumatoid arthritis patients treated with Enbrel for up to 48 months. These included abscess (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in combination with methotrexate, the rates of serious infections were similar among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">could be associated with an increase in the rate of infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were no differences in rates of infection among patients treated with Enbrel and those treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. Serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1 patient reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a serious infection (pneumonia).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">160</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections have been reported in association with Enbrel, including invasive fungal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parasitic (including protozoal), viral (including herpes zoster), bacterial (including </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Listeria</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Legionella</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure-adjusted rate was 0.06 events per 100 patient-years. In postmarketing experience, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately half of all of the case reports of opportunistic infections worldwide were invasive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections. The most commonly reported invasive fungal infections included</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Candida,</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis, Aspergillus, </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt"> Histoplasma</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. Invasive fungal infections accounted for more than half </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the fatalities amongst patients who developed opportunistic infections. The majority of the reports </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a fatal outcome were in patients with </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pneumocystis</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> pneumonia, unspecified systemic fungal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, and aspergillosis (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new positive ANA (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of placebo-treated patients) and by </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crithidia luciliae</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> assay (3% of patients treated with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of long-term treatment with Enbrel on the development of autoimmune diseases is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">unknown.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been rare reports of patients, including rheumatoid factor positive patients, who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Pancytopenia and aplastic anaemia</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">outcomes (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Interstitial lung disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon). There have been postmarketing reports of interstitial lung disease (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Concurrent treatment with anakinra </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia (absolute neutrophil count </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03c;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1000/mm</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). While neutropenic, one patient developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elevated liver enzymes</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the double-blind periods of controlled clinical trials of etanercept across all indications, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">periods of controlled clinical trials that allowed concomitant treatment with etanercept and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">161</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.18% (frequency common).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoimmune hepatitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(frequency uncommon).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">frequency and type to those seen in adult patients. Differences from adults and other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considerations are discussed in the following paragraphs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were generally mild to moderate and consistent with those commonly seen in outpatient paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">populations. Severe adverse events reported included varicella with signs and symptoms of aseptic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the frequency and severity of infections was similar in 58 patients completing 12 months of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Undesirable effects in paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events reported were similar to those seen in previous studies in adults with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest dose level evaluated has been an intravenous loading dose of 32 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous doses of 16 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered twice weekly. One rheumatoid arthritis patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experiencing undesirable effects. There is no known antidote to Enbrel.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, infiltration by inflammatory cells including T-cells leads to increased TNF levels in psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF-binding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to its cell surface receptors and thereby inhibits the biological activity of TNF. TNF and lymphotoxin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cross-linking of cell surface TNFRs. Dimeric soluble receptors such as etanercept possess a higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">element in the construction of a dimeric receptor imparts a longer serum half-life.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">biologically inactive. Etanercept may also modulate biologic responses controlled by additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regulated by TNF.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using American College of Rheumatology (ACR) response criteria. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively; p &lt; 0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">month 6 compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">always occurred by 3 months. A dose response was seen; results with 10 mg were intermediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included disability, vitality, mental health, general health status, and arthritis-associated health status </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improved in patients treated with Enbrel compared to controls at 3 and 6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">magnitudes of responses as patients who received Enbrel without interruption of therapy based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results of open-label studies. Continued durable responses have been seen for up to 10 years in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label extension treatment trials when patients received Enbrel without interruption. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10 mg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel were administered SC twice a week for up to 24 months. Methotrexate doses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the trial and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued for up to 24 months. Clinical improvement including onset of action within 2 weeks with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg was similar to that seen in the previous trials, and was maintained for up to 24 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year 2 of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this study, structural joint damage was assessed radiographically and expressed as change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months. The 10 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel dose had consistently less effect on structural damage than the 25 mg dose. Enbrel 25 mg was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. The results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown in the figure below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">&lt;3 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:78pt"><span style="font-family:Arial,sans-serif;font-size:9.847pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:96pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">0.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">1.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.0</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:322pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:6.892pt">2.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:288pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:289pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">Enbrel 25 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:167pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">12 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:398pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">24 Months</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:147pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:179pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:369pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:405pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:458pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:9.847pt">JSN</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:138pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:155pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:184pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:200pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:229pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.4 0.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:364pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">2.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:409pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">1.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:425pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:453pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:470pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">0.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:279pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:8.857pt">*p &lt; 0.05</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic progression in RA patients treated with Enbrel alone (25 mg twice weekly), methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone (7.5 to 20 mg weekly, median dose 20 mg), and of the combination of Enbrel and methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying antirheumatic drug (DMARD) other than methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks than patients in either of the single therapy groups (results shown in table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:68pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs Methotrexate vs Enbrel in </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoint</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:210pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 228)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 223)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel +</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 231)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.5% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.2% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.8% </span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DAS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:442pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52 score</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.3</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:229pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:56pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HAQ</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:442pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:438pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8</span><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">&#x2020;,</span></b></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.96pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: Patients who did not complete 12 months in the study were considered to be non-responders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: Values for Disease Activity Score (DAS) are means.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: Remission is defined as DAS &lt;1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic progression at 12 months was significantly less in the Enbrel group than in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate group, while the combination was significantly better than either monotherapy at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slowing radiographic progression (see figure below).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">165</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Progression: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">with Methotrexate in Patients with RA of 6 Months To 20 Years Duration (12 Month Results)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate, &#x2020; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf066;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy were also observed after 24 months. Similarly, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed after 24 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an analysis in which all patients who dropped out of the study for any reason were considered to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at 24 months was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate alone groups (62%, 50%, and 36%, respectively; p&lt; 0.05). The difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel alone and methotrexate alone was also significant (p&lt; 0.05). Among patients who completed a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients received placebo, 214 patients received 50 mg Enbrel once weekly and 153 patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparability (non-inferiority) between the two regimens. A single 50 mg/ml injection of Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with psoriatic arthritis. Patients were between 18 and 70 years of age and had active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 swollen joints and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 tender joints) in at least one of the following forms: (1) distal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ankylosis. Patients also had plaque psoriasis with a qualifying target lesion </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:128pt"><span style="font-family:Arial,sans-serif;font-size:9.547pt">Change from Baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">-1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:154pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">-0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">0.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">1.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">2.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">2.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:157pt"><span style="font-family:Arial,sans-serif;font-size:7.957pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">Enbrel </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:368pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">Enbrel + Methotrexate</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:222pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">2.80</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:240pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">0.52*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:253pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">-0.54</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.367pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.367pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.367pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:295pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">1.68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:312pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">0.21*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:325pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">-0.30</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.367pt">&#x2020;</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:367pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">1.12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:384pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">0.32</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:399pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:7.957pt">-0.23</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.367pt">&#x2020;</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.367pt">,</span></sup><sup><span style="font-family:Symbol,sans-serif;font-size:6.367pt">&#xf066;</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:234pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">TSS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:294pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">Erosions</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:380pt"><b><span style="font-family:Arial,Bold,sans-serif;font-size:11.137pt">JSN</span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24%). Patients currently on methotrexate therapy (stable for </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 months) could continue at a stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 25 mg/week methotrexate. Doses of 25 mg of Enbrel (based on dose-finding studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. At the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">end of the double-blind study, patients could enter a long-term open-label extension study for a total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarised in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriatic Arthritis in a Placebo-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:315pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Psoriatic Arthritis Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 50</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  ACR 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  PsARC</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:150pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     Month 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:327pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:399pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: 25 mg Enbrel SC twice weekly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p &lt; 0.001, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:157pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c: p &lt; 0.01, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Enbrel was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients was assessed at every timepoint using the disability index of the HAQ. The disability index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relative to placebo (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Table below. In an analysis in which all patients who dropped out of the study for any reason were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered to have progressed, the percentage of patients without progression (TSS change &#x2264; 0.5) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively, p &#x2264; 0.001). The effect of Enbrel on radiographic progression was maintained in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who continued on treatment during the second year. The slowing of peripheral joint damage was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients with polyarticular symmetrical joint involvement.  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">167</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Mean (SE) Annualized Change from Baseline in Total Sharp Score</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:154pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 104)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n = 101)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Month 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.00 (0.29)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.03 (0.09)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SE = standard error.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p = 0.0001.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit was maintained during the longer-term exposure of up to 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis mutilans psoriatic arthropathies due to the small number of patients studied.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No study has been performed in patients with psoriatic arthritis using the 50 mg once weekly dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen. Evidence of efficacy for the once weekly dosing regimen in this patient population has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">based on data from the study in patients with ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with ankylosing spondylitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing twice weekly administration of 25 mg Enbrel with placebo. A total of 401 patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enrolled from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visual analog scale (VAS) scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for average of duration and intensity of morning stiffness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plus VAS scores of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30 for at least 2 of the following 3 parameters: patient global assessment; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were not included in the study. Doses of 25 mg of Enbrel (based on dose-finding studies in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">138 patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary measure of efficacy (ASAS 20) was a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 20% improvement in at least 3 of the 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Ankylosing Spondylitis in a </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:238pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo-Controlled Trial</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent of Patients</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:161pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Ankylosing Spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:165pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:383pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">168</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  ASAS 70:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:172pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, Enbrel vs. Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b: p = 0.002, Enbrel vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. Responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar in patients who were or were not receiving concomitant therapies at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly vs 25 mg Enbrel administered twice weekly were evaluated in a double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled study of 356 patients with active ankylosing spondylitis. The safety and efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profiles of the 50 mg once weekly and 25 mg twice weekly regimens were similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with non-radiographic axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 1</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meet the modified New York criteria for AS. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in at least three of the four ASAS domains and absence of deterioration in the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">domain. The double-blind period was followed by an open-label period during which all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive Enbrel 50 mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were obtained to assess inflammation at baseline and at weeks 12 and 104.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission and BASDAI 50. Week 12 results are shown in the table below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Endpoints</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double-Blind Clinical</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Responses at Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=106 to 109*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=103 to 105*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS** 40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS partial remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI***50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.8</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*Some patients did not provide complete data for each endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**ASAS=Assessments in Spondyloarthritis International Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">169</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for placebo treated (n=105) patients (p&lt;0.001). At week 104, the mean change from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.40 the spine (n=154).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in most health-related quality of life and physical function assessments, including BASFI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Physical Component Score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">visit (2 weeks) and were maintained through 2 years of therapy. Improvements in health-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life and physical function were also maintained through 2 years of therapy. The 2 year data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">did not reveal any new safety findings. At week 104, 8 subjects had progressed to a score of bilateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthropathy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Study 2</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following 24 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">209 adult patients with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt; 3 mg/l), and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">open-label Enbrel 50 mg weekly plus stable background NSAID at the optimal tolerated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory dosage for 24 weeks in Period 1. Patients were also required to have an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to two or more NSAIDs. At week 24, 119 (57%) patients achieved inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease and entered into the Period 2 40-week withdrawal phase where subjects discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept, yet maintained the background NSAID. The primary measure of efficacy was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 2.1) within 40 weeks following withdrawal of Enbrel. Patients who flared were retreated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg weekly for 12 weeks (Period 3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Period 2, the proportion of patients experiencing &#x2265;1 flare increased from 22% (25/112) at week 4 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 weeks following withdrawal of Enbrel. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additionally compare the time to flare to patients from Study 1 who met the Study 2 withdrawal phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">entry requirements and continued Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24 weeks). Less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 25% of patients in Study 1 who did not have treatment withdrawn experienced a flare over the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">etanercept treatment (Study 1), p&lt;0.0001.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 87 patients who entered Period 3 and were retreated with Enbrel 50 mg weekly for 12 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5 weeks (95% CI: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4-8 weeks).</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">170</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel is recommended for use in patients as defined in section 4.1. Patients who &#x201c;failed to respond </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to&#x201d; in the target population is defined by insufficient response (PASI&lt; 50 or PGA less than good), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration to assess response with at least one of the three major systemic therapies as available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% of the body surface area that were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. One hundred and twelve (112) patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was administered at doses of 25 mg once a week, 25 mg twice a week or 50 mg twice a week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 consecutive months. During the first 12 weeks of the double-blind treatment period, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or one of the above three Enbrel doses. After 12 weeks of treatment, patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment groups continued to week 24 on the dose to which they were originally randomised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. Patients in this study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a dose of 25 mg or 50 mg Enbrel, or placebo twice a week for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 25 mg Enbrel twice weekly for an additional 24 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. Patients in this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study received a dose of 50 mg Enbrel or placebo once weekly for 12 weeks and then all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 50 mg Enbrel once weekly for an additional 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt; 0.0001). At 24 weeks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:173pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Responses of Patients with Psoriasis in Studies 2, 3 And 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respons</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:84pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">e (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">------------------Study 2--------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:196pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">---------------Study 3------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:340pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">---------------Study 4------------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">----------Enbrel---------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--------Enbrel-------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-------Enbrel------</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:183pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:376pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BIW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:467pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:512pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">QW</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:128pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:228pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:328pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:463pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:508pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n = 90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:507pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">wk 24</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:138pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">77*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DSGA</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">almost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:141pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:201pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:294pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:516pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">171</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*p </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.0001 compared with placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of rebound (PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 150% of baseline) and for the time to relapse (defined as a loss of at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least half of the improvement achieved between baseline and week 24). During the withdrawal period, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rebound flare of disease and no psoriasis-related serious adverse events were observed. There was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through week 36. For patients who received 25 mg twice weekly throughout the study, the PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response continued to improve between weeks 12 and 36.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">75 at week 24.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical responses were sustained and safety was comparable to shorter-term studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the choice of intermittent or continuous therapy should be based upon physician judgment and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Antibodies to Enbrel</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These antibodies have all been non-neutralising and are generally transient. There appears to be no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">correlation between antibody development and clinical response or adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.5 years) increases over time, as expected. However, due to their transient nature, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects and psoriasis subjects.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of antibodies observed at each assessment point was up to approximately 9%.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">172</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drug and/or prednisone (&lt; 0.2 mg/kg/day or 10 mg maximum). In part 1, all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received 0.4 mg/kg (maximum 25 mg per dose) Enbrel subcutaneously twice weekly. In part 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in at least three of six and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in no more than one of six JRA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">core set criteria, including active joint count, limitation of motion, physician and patient/parent global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as a </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% worsening in three of six JRA core set criteria and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% improvement in not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more than one of the six JRA core set criteria and a minimum of two active joints.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 116 days for patients who received Enbrel and 28 days for patients who received placebo. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients remaining on Enbrel continued to improve from month 3 through month 7, while those who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo did not improve.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years at time of enrolment) continued to receive Enbrel for up to 10 years. Rates of serious adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events and serious infections did not increase with long-term exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%), and the infections associated with etanercept use were of a more severe nature.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered weekly for 12 weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints and physician global assessment. The safety profile was consistent with that observed in other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA studies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 127 patients in the parent study, 109 participated in the open-label extension study and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical status achieved in the parent study were generally maintained for all efficacy endpoints during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period once during the extension study based on investigator&#x2019;s judgement of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response. 30 patients entered the withdrawal period. 17 patients were reported to have a flare (defined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:770pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as &#x2265; 30% worsening in at least 3 of the 6 ACR Pedi components with &#x2265; 30% improvement in not more </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">173</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel withdrawal was 190 days. 13 patients were re-treated and the median time to re-treatment from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal was estimated as 274 days. Due to the small number of data points, these results should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interpreted with caution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile was consistent with that observed in the parent study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additionally, studies have not been conducted to assess the effects of reducing the recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Enbrel following its long-term use in patients with JIA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &#x2265; 3, involving &#x2265; 10% of the BSA, and PASI &#x2265; 12). Eligible patients had a history of receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more patients randomised to Enbrel had positive efficacy responses (e.g. PASI 75) than those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric Plaque Psoriasis Outcomes at 12 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Enbrel</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0.8 mg/kg Once </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 106)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 105)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (57%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (11%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (75%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (23%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sPGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d;, n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 (53%)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 (13%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abbreviation: sPGA-static Physician Global Assessment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:90pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 compared with placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly for additional 24 weeks. Responses observed during the open-label period were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">those observed in the double-blind period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During a randomised withdrawal period, significantly more patients re-randomised to placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel. With continued therapy, responses were maintained up to 48 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beyond the 48 week study discussed above. Long-term experience with Enbrel was generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable to the original 48-week study and did not reveal any new safety findings. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">method, which may detect ELISA-reactive degradation products as well as the parent compound.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">174</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration approximately 48 hours after a single dose. The absolute bioavailability is 76%. With </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as those observed after single doses. After a single subcutaneous dose of 25 mg Enbrel, the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum serum concentration observed in healthy volunteers was 1.65 </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.66</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml, and the area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">under the curve was 235</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b1;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 96.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean serum concentration profiles at steady state in treated RA patients were C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 2.4 mg/l vs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 mg/l, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. In an open-label, single-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg/ml injection was found to be bioequivalent to two simultaneous injections of 25 mg/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state AUCs were 466</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml and 474</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hr/ml for 50 mg Enbrel once weekly (N = 154) and 25 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">twice weekly (N = 148), respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A biexponential curve is required to describe the concentration time curve of etanercept. The central </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Etanercept is cleared slowly from the body. The half-life is long, approximately 70 hours. Clearance is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.11 l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no apparent pharmacokinetic difference between males and females.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Linearity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">across the dosing range.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to patients and volunteers, increased etanercept concentrations were not observed in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acute renal failure. The presence of renal impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Increased etanercept concentrations were not observed in patients with acute hepatic failure. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presence of hepatic impairment should not require a change in dosage.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Elderly</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">estimates in patients less than 65 years of age.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">175</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were administered 0.4 mg Enbrel/kg twice weekly for three months. Serum concentration profiles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had reduced clearance (increased clearance when normalised by weight) compared with older children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">age) will have serum levels close to those seen in adults, younger children will have appreciably lower</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric patients with plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8 mg/kg (up to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week) of etanercept once weekly for up to 48 weeks. The mean serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48. These mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum dose of 50 mg per week). These mean concentrations were similar to those seen in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with plaque psoriasis treated with 25 mg etanercept twice weekly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was considered to be non-genotoxic from a battery of </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> studies. Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to the development of neutralising antibodies in rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. Enbrel did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC-based serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug concentrations that were over 27-fold higher than that obtained in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 25 mg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sucrose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium chloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">L-Arginine hydrochloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate monobasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium phosphate dibasic dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30 months.</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">176</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel may be stored at temperatures up to a maximum of 25&#xb0;C for a single period of up to four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">four weeks of removal from refrigeration.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Keep the dose-dispenser cartridges in the outer carton in order to protect from light.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose-dispenser cartridge with integrated 25 mg pre-filled Enbrel syringe. The pre-filled syringe inside </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the dose-dispenser cartridge is made from clear type 1 glass with a staked stainless steel 27 gauge </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needle, rigid needle cover, and rubber stopper. The rigid needle cover of the pre-filled syringe contains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dry natural rubber (a derivative of latex). See section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 4, 8 or 24 Enbrel dose-dispenser cartridges with 8, 16 or 48 alcohol swabs. Not all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dose-dispenser cartridge with integrated 50 mg pre-filled Enbrel syringe. The pre-filled syringe inside </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the dose-dispenser cartridge is made from clear type 1 glass with a staked stainless steel 27 gauge </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needle, rigid needle cover, and rubber stopper. The rigid needle cover of the pre-filled syringe contains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dry natural rubber (a derivative of latex). See section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cartons contain 2, 4 or 12 Enbrel dose-dispenser cartridges with 4, 8 or 24 alcohol swabs. Not all pack </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:99pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Instructions for use and handling</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before injection, Enbrel dose-dispenser cartridges should be allowed to reach room temperature </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(approximately 15 to 30 minutes). The needle cover should not be removed while allowing the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose-dispenser cartridge to reach room temperature. By looking through the inspection window, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solution should be clear to slightly opalescent, colourless to pale yellow or pale brown and may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">contain small white or almost transparent particles of protein. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comprehensive instructions for the preparation and administration of Enbrel dose-dispenser cartridge </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are given in the package leaflet and in the user manual provided with the SMARTCLIC device.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product (dose-dispenser cartridge) is for single use only in conjunction with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SMARTCLIC device.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pfizer Europe MA EEIG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Boulevard de la Plaine 17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1050 Bruxelles</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Belgium</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:291pt"><span style="font-family:Arial,sans-serif;font-size:8.04pt">177</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 25 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/027</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/028</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/029</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Enbrel 50 mg solution for injection in dose-dispenser cartridge</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/030</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/031</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/99/126/032</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 03 February 2000</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of last renewal: 26 November 2009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000fd">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span></p>
</div>










































































































































































</body>
</html> 

